Navigation Links
Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
Date:1/28/2010

ch includes both the HeartMate II® LVAS (Left Ventricular Assist System) and HeartMate® XVE, increased 43 percent year-over-year," said Gary F. Burbach, president and chief executive officer of Thoratec.

The company said that it ended the year with 120 HeartMate II centers in North America, an increase of 19 during the year, and 91 internationally, an increase of 14 during 2009. In addition, there are now 76 centers with CMS (Centers for Medicare and Medicaid Services) certification for reimbursement for Destination Therapy (DT).

"We are looking forward to rolling out the HeartMate II for DT, based on the FDA's approval of our PMA (Pre-Market Approval) supplement on January 20, 2010.  This approval creates a new opportunity for the many advanced-stage heart failure patients who are not responding to other forms of treatment to access a proven therapy. We have launched a comprehensive strategy targeted to existing and potential centers, referring cardiologists and patients to build awareness around the efficacy of the device and its ability to dramatically improve survival and quality of life versus other therapy options," Burbach noted.

With this approval, the HeartMate II can be used to provide long-term cardiac support for patients suffering from advanced-stage heart failure who are not eligible for transplantation. Under the approval, the HeartMate II can be used in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation.  

"We begin 2010 in an excellent position to achieve continued strong growth. The clinical community's response to the data from the DT trial has been very positive and we expect a significant numbe
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... found, results showed CYPHER(R) Stent ... had lower mortality and heart attack rates, ... patient data from a two-year randomized controlled trial comparing,the ... no,statistically significant differences in safety outcomes between the two,drug- ...
... Clinical investigators at the,European Society of Cardiology Congress ... Coronary Stent continued to,provide clinical benefits compared to a ... years of follow-up with no differences in safety. ... arm of the,study continued to be significantly less likely ...
Cached Medicine Technology:Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 2Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 3Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... pink race gear on e Bay in favor of Susan ... Awareness month and pink is// the symbolic color of Breast ... Racing to create exclusive warriors in pink livery with exclusive ... the eBay auction. ,Parts of the Warrior in ...
... a team of researchers from the Edinburgh University, the risk ... a variant of a gene called// neuregulin. ,This ... high risk of developing schizophrenia were monitored for 10 years ... the volunteers had 2 or more relatives affected by this ...
... packets of counterfeit condoms of Durex best-selling 'extra safe' range ... ,A Durex spokeswoman stated that the company could not 'guarantee ... that were on sale in UK was also unknown,These counterfeits ... When tests were conducted at the company's laboratories it was ...
... which could protect children from meningococcal disease is being ... disease has not been// available. ,The researchers, ... Child Health Research and Princess Margaret Hospital for Children, ... meningococcal B strain which is the most common. It is ...
... Monday called for fast tracking of the approval ... effective against extremely drug resistant// tuberculosis(XDR-TB) which is ... ,MSF otherwise called Doctors Without Borders(DWB) has ... Food and Drug Administraton(USFDA) and European Medicines Agency ...
... must have spice in every Indian home now finds itself ... uses to fight// many tubborn inflammations and degenerative disorders thus ... scripts of Ayurveda. ,According to a recent study ... Janet L. Funk, MD, working with Barbara N. Timmermann, PhD ...
Cached Medicine News:Health News:Gene Variant associated with Schizophrenia identified 2Health News:Faster Approval Procedures Urged For New TB Drugs 2
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
Medicine Products: